CIAS
SNDX icon

Capital Investment Advisory Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Capital Investment Advisory Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-500
Closed -$4K – 1141
2019
Q3 		$4K Hold
500
– – ﹤0.01% 1179
2019
Q2 		$5K Buy
+500
New +$3.65K ﹤0.01% 1141

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Investment Advisory Services's SNDX Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Syndax Pharmaceuticals (SNDX) in Q4 2019, closing a stake of 500 shares — an estimated $4K sold.

Capital Investment Advisory Services first reported a position in SNDX in Q2 2019 and held it in 2 quarters. The position peaked at $5K in Q2 2019. 72 funds tracked by Wall St. Rank hold SNDX as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Syndax Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 500 Syndax Pharmaceuticals shares in Q4 2019, an estimated $4K.
  • Capital Investment Advisory Services first reported a position in Syndax Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Capital Investment Advisory Services's Syndax Pharmaceuticals position peaked at $5K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.